INFORCE 3®

TRUST THE INTRANASAL RESPIRATORY VACCINE YOU'VE COUNTED ON FOR THE LAST DECADE.

INFORCE 3® is an innovative vaccine that protects beef and dairy cattle from common pneumonia-causing viral pathogens: bovine respiratory syncytial virus (BRSV), infectious bovine rhinotracheitis (IBR) and parainfluenza 3 (PI_3).

LET'S TAKE A LOOK: SIDE-BY-SIDE PROTECTION FROM INFORCE 3® AND NASALGEN® 3.

	INFORCE 3®	NASALGEN® 3
Shown Effective Against Disease Caused By	BRSV, IBR, PI_3	BRSV, IBR, PI_3
Safety	Demonstrated safe for use in very young, high-stress calves; weaned and high-stress stocker calves; pregnant heifers and cows.	Safe for use in pregnant cows and in calves nursing pregnant cows, as well as young calves.
Administration	Intranasal, 2 mL (one nostril)	Intranasal, 2 mL (one nostril)
Duration of Immunity (DOI)	193 days (IBR)	195 days (IBR)
IBR and PI_3 Viral Replication	Unique temperature-specific viruses limit replication in the upper respiratory tract to cause less stress and better imitation of natural viral infection[1]	Typical modified live viruses replicate throughout the body and require the immune system to stop replication[1]
Confidence	Launched in 2010; 200 million doses sold[2]	Launched in 2020
Available sizes	1 dose, 10 dose, 25 dose, 50 dose	1 dose, 10 dose, 50 dose

zoetis

INFORCE 3®

MARKET-LEADING PRODUCT THAT HAS EARNED PRODUCERS' TRUST

Respiratory protection as early as 3 days of age

The leading cattle vaccine on the market since 2015[2], INFORCE 3 respiratory vaccine helps trigger a quick, local immune response and primes the immune system for a memory response to disease challenges.[3]

INFORCE 3 offers your calves a trusted first line of defense.

- Effective single-nostril administration
- Complements maternal antibodies[4,5]

Additionally, INFORCE 3 helps offset the risk for pneumonia in adult dairy cows when given shortly before or on the day of calving.

INFORCE 3 means:

MORE healthy calves, heifers and cows

FEWER culls

FEWER losses from pneumonia and viral agents or pathogens causing bovine respiratory disease (BRD).

[1] Grissett GP, et al. Effect of Ambient Temperature on Viral Replication and Serum Antibody Titers Following Administration of a Commercial Intranasal Modified-Live Infectious Bovine Rhinotracheitis-Parainfluenza-3 Virus Vaccine to Beef Cattle Housed in High- and Moderate-Ambient Temperature Environments. *Am J Vet Res.* 2014:75(12):1076-1082.

[2] Animalytix® historical data, April 2020, Zoetis Inc.

[3] Stokka GL, Neville B, Seeger JT, Stoltenow C, Dyer N, Gaspers JJ. Evaluation of the serologic effect of concurrent IBR, BRSV, PI3 and Mannheimia vaccination and time interval between the first and second dose on the subsequent serological response to the Mannheimia toxoid and BRSV fractions on spring-born beef calves in North Dakota. North Dakota Beef Report. 2014;40-42.

[4] Mahan SM, Sobecki B, Johnson J, et al. Efficacy of intranasal vaccination with a multivalent vaccine containing temperature-sensitive modified-live bovine herpesvirus type 1 for protection of seronegative and seropositive calves against respiratory disease. J Am Vet Med Assoc. 2016;248(11):1280-1286.

[5] Ellis JA, Gow SP, Mahan S, Leyh R. Duration of immunity to experimental infection with bovine respiratory syncytial virus following intranasal vaccination of young passively immune calves. J Am Vet Med Assoc. 2013;243(11):1602-1608

zoetis